Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (HD). However, its use is limited by a high primary failure rate (~30%) and frequent interventions (50–60%) within the first year to maintain patency. Current evidence is constrained by variability in preoperative doppler mapping cutoff values, reliance on expert opinion in guidelines, and predominantly single-center designs. Few studies include histological data, and most associate histopathology with maturation failure rather than with thrombosis or long term AVF survival.
Objectives: Identify patients’ factors (demographic, clinical, biochemical, and echocardiographic) associated with AVF thrombosis. Identify vascular access factors (preoperative Doppler ultrasound, arterial and venous histology) associated with AVF thrombosis. Evaluate dermal histology at AVF creation as a novel factor. Determine which thrombosis associated factors also affect AVF survival.
Prospective cohort study conducted at the National Hospital of Clinics, National University of Córdoba, Argentina. Patients were recruited over a 2-year period (October 2019 to October 2023) and followed for a minimum of 2 years, with a maximum follow up of 4 years. The study was approved by the Institutional Ethics Committee and adheres to the Declaration of Helsinki and to the Declaration of Istanbul on Organ Trafficking and transplant tourism. Inclusion Criteria: Adults, first AVF creation, echocardiogram, laboratory tests conducted within 30 days prior to enrollment, preoperative doppler ultrasound mapping, Informed consent obtained for arterial, venous, and skin biopsies at the time of AVF creation. Exclusion Criteria: autoimmune, hematological, or oncological diseases, life expectancy less than 6 months, severe protein-calorie malnutrition and pregnant women. Survival analysis and regression models adjusted for baseline variables were used to identify factors associated with thrombosis and survival patency. A p-value less than 0.05 was considered statistically significant. Statistical analyses were performed using Stata version 17.
Thirty-eight patients participated in the study, with an average age of 69 years. Among them, 55.3% were male, 57.8% had diabetes, 18.9 % reduced ejection fraction, 39.4% had coronary artery disease, and 55.2% had peripheral vascular disease. The AVFs performed were: humero-cephalic (57.8%), basilic (31.6%), and radio-cephalic (10.5%). The incidence of AVF thrombosis was 49.5% during the first year and increased to 56.1% by the second year. Definitive AVF loss at 2 years was 40%.
AVF thrombosis is a common complication in hemodialysis patients. Among the factors studied, preoperative venous distensibility was the only one associated with both thrombosis and improved AFV survival. Histological analysis revealed that a larger tied venous diameter correlated significantly with lower arterial and dermal fibrosis but higher venous fibrosis, underscoring the critical role of these tissue characteristics in arteriovenous fistulae function and longevity and may inform future therapeutic targets to enhance AVF outcomes.
